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Polycystin-1 and -2  
are pressure sensors
Sharif-Naeini et al., Cell 2009; 139: 587–596; doi:10.1016/j.cell.2009.08.045
Mutations in the genes PKD1 and PKD2, which encode the pro-
teins polycystin-1 (TRPP1) and polycystin-2 (TRPP2), respectively, 
account for most cases of autosomal-dominant polycystic kidney 
disease. TRPP1 is a large membrane protein with 11 transmembrane 
domains and a long amino-terminal extracellular domain involved 
in cell–cell and cell–matrix interactions as well as cell signaling. 
TRPP1 interacts with TRPP2, also a membrane protein and a mem-
ber of the TRP ion channel family. It was proposed that TRPP1 and 
TRPP2 associate through their cytosolic carboxy-terminals and form 
a ‘receptor–ion channel complex.’ TRPP1 and TRPP2 colocalize at 
the membrane of the primary cilia of renal epithelial and endothelial 
cells, where they are believed to transduce changes in luminal shear 
stress (that is, fluid flow parallel to the cell surface) into a calcium 
signal. It has been suggested that TRPP1 acts as a mechanical sensor 
that regulates opening of the calcium-permeable TRPP2. Thus, loss 
of this mechanosensory function (that is, flow sensing) would result 
in altered cellular signaling, leading to cyst formation. Nonetheless, 
how polycystins contribute to cellular mechanosensitivity remains 
obscure. Interestingly, polycystins are also abundantly expressed 
in arterial myocytes, which, instead of responding to shear stress, 
respond to the intraluminal pressure that causes wall stretch. An 
increase in intraluminal pressure causes a gradual depolarization of 
the vascular smooth muscle cells that is due to the opening of non-
selective stretch-activated cation channels. In turn, depolarization 
of the cell membrane opens voltage-gated calcium channels, hence 
increasing intracellular Ca2+ and inducing myocyte constriction (the 
myogenic or Bayliss response). In a recent communication, Sharif-
Naeini et al. examined whether polycystins could be involved in 
pressure sensing. They found that TRPP2 inhibited stretch-activated 
ion channels. However, coexpression with TRPP1 reversed this inhi-
bition, indicating that the TRPP1/TRPP2 ratio regulates pressure 
sensing. They also found that deletion of TRPP1 in smooth muscle 
cells reduced the activity of stretch-activated cation channels as well 
as the arterial myogenic tone (Figure). Inversely, depletion of TRPP2 
in TRPP1-deficient arteries rescued both the opening of stretch-
activated cation channels and the myogenic response. Finally, the 
authors also found that TRPP2 interacted with filamin A and that 
this actin-cross-linking protein was critical for regulation of stretch-
activated cation channels. This work uncovers a role for polycystins 
in regulating pressure sensing.
Juan Oliver
Renal impairment  
in pure autonomic failure
Garland et al., Hypertension 2009; 54: 1057–1061; doi:10.1161/
HYPERTENSIONAHA.109.136853
Hypertension accelerates renal damage and likely causes primary 
renal disease. Elderly people have a significant decline in renal func-
tion that has been attributed to their increase in arterial pressure. 
Interestingly, in normal subjects, arterial pressure displays a charac-
teristic diurnal pattern, with a significant decline during sleep and an 
increase around the time of awakening. In the elderly, arterial pres-
sure is not only more frequently elevated but also more variable, and 
abnormal circadian rhythm of arterial pressure is more common. 
The contribution of arterial pressure variability to the homeostasis 
of the cardiovascular system and renal function is currently unclear. 
Patients with pure autonomic failure (PAF) present an interesting 
model in blood pressure regulation because they all have severe 
orthostatic hypotension (drops in systolic arterial pressure of ≥20 
mm Hg are common, and decreases of ≥50 mm Hg are not unu-
sual), but supine hypertension is present in approximately half of the 
patients. Managing the supine hypertension in these patients can be 
challenging, because treatment can worsen orthostatic hypotension. 
The supine hypertension in patients with PAF has been associated 
with left ventricular hypertrophy, but damage in the kidney has not 
been assessed. Garland et al. examined this question by reviewing 
hemodynamic and laboratory data of 64 male patients with PAF. In 
these patients, systolic blood pressure fell by 67 ± 40 mm Hg within 
10 minutes of standing, with an inappropriately low increase of 13 
± 11 bpm in heart rate. Plasma norepinephrine levels in the patients 
were below normal (0.62 ± 0.32 nmol/l supine and 1.28 ± 1.25 nmol/l 
standing). When compared with the levels of appropriate normal 
controls, serum creatinine and blood urea nitrogen levels were 
elevated in patients with PAF. Of the patients with PAF, 48% had 
Pkd1 inactivation impairs the mesenteric artery myogenic response. 
Changes in lumen diameter in Pkd1+/+ (top panel) and Pkd1SMdel/del 
(lower panel) arteries as a function of pressure.
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Systolic arterial pressure in patients with PAF stratified as those with and 
without supine hypertension.
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unfortunately, does not happen. Patient care needs to be individual-
ized—more intensive therapy may be required for the treatment of 
hyperkalemia, metabolic acidosis, or extreme hypercatabolism—and 
the true adequacy of renal replacement therapy is defined by more 
than just the clearance of small solutes.
Marc De Broe
1N Engl J Med 2008; 359: 7–20. 2N Engl J Med 2009; 361: 1699–1701.
A peptide-based  
erythropoietin-receptor agonist  
for pure red-cell aplasia
Macdougall et al., N Engl J Med 2009; 361: 1848–1855
Trials in anemia management have examined the impact of anemia 
correction on cardiovascular outcomes. Although the association 
between anemia and cardiovascular disease suggested that anemia 
correction would reduce cardiovascular disease, trials demonstrated 
that therapy with an erythrocyte-stimulating agent as compared with 
placebo, or when dosed to a higher target, resulted in no benefit or 
harm, respectively.1,2 Pure red-cell aplasia (PRCA) has been linked to 
the development of anti-erythropoietin antibodies and described in 
patients receiving a certain formulation of epoetin-alfa.3 Treatment 
options described thus far have included steroids, cyclosporine, intra-
venous immunoglobulin, and rituximab.4 Macdougall et al. describe 
the use of a novel, synthetic, peptide-based erythropoietin-receptor 
agonist (Hematide) to stimulate erythropoiesis in patients with ane-
mia that is worsened by this complication of epoetin-alfa therapy. 
Fourteen patients with chronic kidney disease with PRCA or hypo-
plasia were treated subcutaneously with the synthetic peptide-based 
erythropoietin-receptor agonist at a dose of 0.05 mg per kilogram of 
body weight every 4 weeks for a median of 28 months. Thirteen of 
the 14 patients reached the primary end point of a hemoglobin con-
centration above 11 g/dl without regular transfusions. The median 
hemoglobin concentration increased from 9.0 g/dl, previously main-
tained with transfusions, to 11.4 g/dl in the cohort overall. Transfu-
sion requirements decreased dramatically within 12 weeks after the 
first dose. One patient subsequently was found to have antibodies 
against the agonist, and one patient died 4 months after the last dose 
of the agonist. A grade 3 or 4 adverse event occurred in seven other 
patients during the study period, but given the lack of a comparator 
group and the severity of illness of the patients studied, it is difficult 
to evaluate the safety of this treatment.
The natural history of PRCA in patients with anemia receiving 
erythropoiesis-stimulating agents is not well established but has not 
been documented to include a spontaneous recovery. This study does 
not have a comparator group, but one could argue that, given what is 
known about the clinical course of PRCA, such a group is neither ethi-
cal nor necessary. While a true evaluation of the safety of the agonist 
will be done in its phase III studies and arguably should be done in 
additional studies in PRCA, these data strongly suggest that it is ben-
eficial in the management of anemia in patients with this condition.
Lynda Szczech
1N Engl J Med advance online publication, 30 October 2009, doi:10.1056/NEJMoa0907845. 
2N Engl J Med 2006; 355: 2085–2098. 3Blood 2005; 106: 3343–3347. 4Am J Kidney Dis 2004; 
44: 757–761.
supine hypertension (supine systolic blood pressure ≥150 mm Hg) 
(Figure). In this group, as compared with patients with PAF who did 
not have supine hypertension, serum creatinine was higher (133 ± 44 
versus 106 ± 27 µmol/l) and estimated glomerular filtration rate was 
lower (57 ± 22 versus 70 ± 20 ml/min per 1.73 m2). These findings 
suggest that supine hypertension in patients with PAF contributes 
to a decrease in renal function.
Juan Oliver
Intensity of continuous  
renal replacement therapy  
in critically ill patients
RENAL Replacement Therapy Study Investigators, N Engl J Med 2009; 
361: 1627–1638
Bellomo and colleagues present the results of the Randomized Eval-
uation of Normal versus Augmented Level (RENAL) Replacement 
Therapy Study, conducted at multiple centers in Australia and New 
Zealand. In the RENAL study, patients with severe acute kidney injury 
who required intensive care were randomly assigned to receive con-
tinuous venovenous hemodiafiltration at a total effluent flow rate of 
either 25 or 40 ml per kilogram of body weight per hour. The study 
therapy was continued until the recovery of kidney function or until 
the patient’s condition was stable enough to warrant discharge from 
intensive care. In both treatment groups, 45% of patients died in the 
first 90 days after randomization (odds ratio, 1.00; 95% confidence 
interval, 0.81–1.23) (Figure). Overall, 94% of patients who were alive 
after 90 days no longer required dialysis, with similar rates of recovery 
of kidney function in the two treatment groups. In critically ill patients 
with acute kidney injury, treatment with higher-intensity continuous 
renal replacement therapy did not reduce mortality at 90 days. The 
RENAL study confirms the results of the Acute Renal Failure Trial 
Network Study demonstrating no improvement of the outcome with 
more intensive renal replacement therapy in critically ill patients.1,2 As 
Palevsky points out in his editorial comment on the RENAL study,2 
the results of both studies do imply that increasing the intensity of 
renal replacement therapy beyond a threshold dose necessary to 
optimize clinical outcomes does not provide further clinical benefit. 
Thus, it is critical to attain this minimal dosing threshold, which often, 
Kaplan–Meier estimates of the probability of death. Mortality at 28 days was similar 
in the higher-intensity and lower-intensity treatment groups (38.5% and 36.9%, 
respectively), and mortality at 90 days was the same (44.7%) in the two groups.
RE
N
A
L 
Re
pl
ac
em
en
t T
he
ra
py
 S
tu
dy
 
In
ve
st
ig
at
or
s/
N
 E
ng
l J
 M
ed
